AntriaBio

AntriaBio is a biopharmaceutical company with a platform to develop novel extended release therapies. Our platform combines proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.
Type
Public
HQ
Louisville, US
Founded
2010
Size (employees)
19 (est)
AntriaBio was founded in 2010 and is headquartered in Louisville, US

AntriaBio Office Locations

AntriaBio has an office in Louisville
Louisville, US (HQ)
1450 Infinite Dr

AntriaBio Metrics

AntriaBio Financial Metrics

Net income (2016)

($14.9 m)

Market capitalization (28-Apr-2017)

$43 m

Closing share price (28-Apr-2017)

$1.1

Cash (30-Jun-2016)

$4.1 m
AntriaBio's current market capitalization is $43 m.
FY, 2014FY, 2015FY, 2016

Operating expense total

$5.2 m$10.7 m$15 m

EBIT

($5.2 m)($10.7 m)($15 m)

Net Income

($9.7 m)($11.4 m)($14.9 m)
FY, 2014FY, 2015FY, 2016

Cash

$5.9 m$5.3 m$4.1 m

Accounts Receivable

Inventories

$289.6 k$67.2 k

Current Assets

$6.3 m$6.1 m$4.5 m

Total Assets

$7.4 m$11.3 m$10.9 m

Accounts Payable

$460.3 k$1.4 m$1.5 m

Current Liabilities

$964 k$1.7 m$1.7 m

Non-Current Liabilities

$33.9 k$503.6 k$400 k

Total Liabilities

$997.9 k$2.2 m$2.1 m

Additional Paid-in Capital

$24.1 m$38.1 m$52.8 m

Retained Earnings

($17.7 m)($29.1 m)($44 m)

Total Equity

$6.4 m$9.1 m$8.8 m

Financial Leverage

1.2 x1.2 x1.2 x
FY, 2014FY, 2015FY, 2016

Net Income

($9.7 m)($11.4 m)($14.9 m)

Depreciation and Amortization

$7.8 k$128.9 k$744 k

Accounts Receivable

Inventories

$222.4 k

Accounts Payable

Cash From Operating Activities

($3.2 m)($7.1 m)($10.5 m)

Purchases of PP&E

($70 k)($3.1 m)($2.1 m)

Cash From Investing Activities

($830.2 k)($3.6 m)($1.5 m)

Cash From Financing Activities

$9.9 m$10 m$10.7 m

Interest Paid

$15.7 k

Income Taxes Paid

AntriaBio Market Value History

AntriaBio Online Presence

AntriaBio Company Life

You may also be interested in